Serve aiuto per la tesi? Contattaci subito!
1. Morens, D. M.; Folkers, G. K.; Fauci, A. S. The challenge of emerging and re-emerging
infectious diseases. Nature 2004, 430, 242–249.
2. Feldmann, H.; Czub, M.; Jones, S.; Dick, D.; Garbutt, M.; Grolla, A.; Artsob, H.
Emerging and re-emerging infectious diseases. Med. Microbiol. Immunol. 2002, 191,
63–74.
3. Fauci, A. S. Infectious diseases: considerations for the 21st century. Clin. Infect. Dis.
2001, 32, 675–685.
4. Gomez, L.; Clavel, A.; Castillo, J.; Seral, C.; Rubio, C. Emerging and reemerging
pathogens. Int. J. Antimicrob. Agents 2000, 16, 335–339.
5. Fraser, C. M. A genomics-based approach to biodefence preparedness. Nat. Rev. Genet.
2004, 5, 23–33.
6. Bronze, M. S.; Greenfield, R. A. Preventive and therapeutic approaches to viral agents of
bioterrorism. Drug Discov. Today 2003, 8, 740–745.
7. Mairuhu, A. T. A.; Brandjes, D. P. M.; van Gorp, E. C. M. Treating viral hemorrhagic
fever. Idrugs 2003, 6, 1061–1066.
8. Kuiken, T.; Fouchier, R.; Rimmelzwaan, G.; Osterhaus, A. Emerging viral infections in a
rapidly changing world. Curr. Opin. Biotechnol. 2003, 14, 641–646.
9. Gubler, D. J. The global emergence/resurgence of arboviral diseases as public health
problems. Arch. Med. Res. 2002, 33, 330–342.
10. Khabbaz, R. F. Emerging viral infections. Adv. Pediatr. Infect. Dis. 1999, 14, 1–27.
11. Andrei, G.; De Clercq, E. Molecular approaches for the treatment of hemorrhagic fever
virus infections. Antiviral Res. 1993, 22, 45–75.
12. De Clercq, E. Molecular targets for antiviral agents. J. Pharmacol. Exp. Ther. 2001, 297,
1–10.
13. De Clercq, E. Antiviral agents: characteristic activity spectrum depending on the
molecular target with which they interact. Adv. Virus Res. 1993, 42, 1–55.
14. Huggins, J. W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a
broad-spectrum antiviral drug. Rev. Infect. Dis. 1989, 11 (Suppl. 4), S750–S761.
15. Witkowski, J. T.; Robins, R. K.; Sidwell, R. W.; Simon, L. N. Design, synthesis, and
broad spectrum antiviral activity of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
and related nucleosides. J. Med. Chem. 1972, 15, 1150–1154.
16. Sidwell, R.W.; Huffman, J. H.; Khare, G. P.; Allen, L. B.;Witkowski, J. T.; Robins, R. K.
Broad-spectrum antiviral activity of virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-
carboxamide. Science 1972, 177, 705–706.
17. Sidwell, R. W. Ribavirin: a review of antiviral efficacy. Recent Res. Dev. Antimicrob.
Agents Chemother. 1996, 1, 219–256.
18. Bray, M.; Huggins, J. Antiviral therapy of haemorrhagic fevers and arbovirus infections.
Antiviral Ther. 1998, 3, 53–79.
19. American Academy of Pediatrics. Reassessment of the indications for ribavirin therapy
in respiratory syncytial virus infections. Pediatrics 1996, 97, 137–140.
20. Wray, S. K.; Gilbert, B. E.; Noall, M.W.; Knight, V. Mode of action of ribavirin—effect
of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral
Res. 1985, 5, 29–37.
21. Streeter, D. G.;Witkowski, J. T.; Khare, G. P.; Sidwell, R.W.; Bauer, R. J.; Robins, R. K.;
Simon, L. N. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-
carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci.
U.S.A. 1973, 70, 1174–1178.
22. Tam, R. C.; Lau, J. Y. N.; Hong, Z. Mechanisms of action of ribavirin in antiviral
therapies. Antiviral Chem. Chemother. 2001, 12, 261–272.
23. Reyes, G. R. Ribavirin: recent insights into antiviral mechanisms of action. Curr. Opin.
Drug Discov. Dev. 2001, 4, 651–656.
24. Snell, N. J. C. Ribavirin—current status of a broad spectrum antiviral agent. Expert
Opin. Pharmacother. 2001, 2, 1317–1324.
